CD19 and Miyoshi myopathy: Both large (high forward and side scatter properties: monoctytoid gates) and small (low forward and side scatter: lymphocyte gates) subsets of CD19+ CD20+ B cells in MM PBMC, as identified by either anti-CD19 (Table 2) or anti-CD20 (Table 3), resist serotherapy with anti-CD20.